Abstract
Pulmonary adverse events are common abnormalities associated with the use of dasatinib in chronic myeloid leukemia. We present a case of a 69-year-old man who suddenly developed a rare chylothorax pulmonary adverse event following 10 months of dasatinib treatment.
Cite
CITATION STYLE
APA
Baloch, Z. Q., Abbas, S. A., Bhatti, H., Braver, Y., & Ali, S. K. (2017). Dasatinib-induced chylothorax in chronic myeloid Leukemia. Baylor University Medical Center Proceedings, 30(1), 71–73. https://doi.org/10.1080/08998280.2017.11929535
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free